April 2, 2020
Takeda Pharmaceutical said on April 1 that its antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) in combination with chemotherapy gained the backing of a key European advisory panel as a front-line treatment for systemic anaplastic large cell lymphoma (sALCL). The European...read more